PG4

Phase 3Biologic

Pfizer

PG4 is one of 3 biologic programs targeting Pneumococcal Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pneumococcal DiseaseRecruiting

Pneumococcal DiseasePhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Pneumococcal Disease

#DrugCompanyPhaseTrials

Pneumococcal Vaccine

GSK

Approved

1 2

PG4

Pfizer

Phase 3

4 3

PCV15

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Pneumococcal Disease

NCT06524414

Q4 2027

Phase 1Active, not recruiting

Streptococcus Pneumoniae

NCT07086677

Phase 3Recruiting

Pneumococcal Disease

NCT07660198

Q4 2028

Phase 3Recruiting

Pneumococcal Disease

NCT07573462

Q2 2029

Phase 3Recruiting

Pneumococcal Disease

NCT07629440

Clinical

Trials by Indication[1]

Pneumococcal Disease4 trials

A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants

Active, not recruiting· Pfizer logo

Pfizer·Phase 2·NCT06524414·605 enrolled

A PHASE 3, RANDOMIZED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07573462·2,400 enrolled

A PHASE 3, RANDOMIZED DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A CATCH-UP VACCINATION REGIMEN OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN AND ADOLESCENTS

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07660198·1,200 enrolled

Show 1 more trial

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07629440·3,230 enrolled

Children1 trial

A Study to Learn About How a New Pneumococcal Vaccine Works in Children

Completed· Pfizer logo

Pfizer·Phase 2·NCT06531538·225 enrolled

Streptococcus Pneumoniae1 trial

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT07086677·380 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for PG4. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PG4 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PG4. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Pfizer

PG4

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q4 2028

Q2 2029

Trials by Indication[1]

Pneumococcal Disease4 trials

Children1 trial

Streptococcus Pneumoniae1 trial

References

Drug Info

Quick Facts

Related News